Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control

Eitemau Tebyg

• Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
  gan: Wajja, A, et al.
  Cyhoeddwyd: (2023)
• The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
  gan: Wajja, A, et al.
  Cyhoeddwyd: (2017)
• Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
  gan: Wajja, A, et al.
  Cyhoeddwyd: (2018)
• DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
  gan: Mcshane, H
  Cyhoeddwyd: (2008)
• A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
  gan: Rowland, R, et al.
  Cyhoeddwyd: (2012)